The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...